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Abstract
In our endeavor to recognize outstanding contributions in the field of translational medicine, the
Editorial Board of the Journal of Translational Medicine (JTM) in collaboration with Global
Translational Medicine at Pfizer established "The Excellence in Translational Medicine Award"
in May 2006. Fifteen nominated papers from investigators representative of eight countries
covering a wide range of disciplines published in JTM between 1 July 2006 and 30 June 2007 were
evaluated. The four finalists and the winner are announced in this editorial.
Editorial
In our endeavor to recognize outstanding contributions in
the field of translational medicine, the Editorial Board of
the Journal of Translational Medicine (JTM) established
"The Excellence in Translational Medicine Award" in May
2006 [1].
The recipient of "The Excellence in Translational Medicine
Award" will receive a $2,500 prize sponsored by Global
Translational Medicine, Pfizer Global Research and Develop-
ment to cover expenses for any meeting sponsored by a
non-for-profit organization that is relevant to the goal of
translational medicine and research.
Fifteen nominated papers from investigators representa-
tive of eight countries covering a wide range of disciplines
published in JTM between 1 July 2006 – 30 June 2007
were evaluated. For this purpose, an Award Committee*
comprised of ten members of the Editorial Board selected
and co-chaired by Richard J. Ablin (University of Arizona
College of Medicine and the Arizona Cancer Center, Tuc-
son, AZ) and Yi-Xin Zeng (Sun Yat-sen University Cancer
Center, Guangzhou, China) was formed. The National
Institutes of Health Scoring System of 1–5, with 1 = Out-
standing and 5 = Poor were used with the papers being
evaluated with regard to their:
• Scientific merit
• Originality
• Clarity
• Relevance to the purposes of translational medicine and
research
• Research design
• Methodology
The competition, judged from the closeness of the scores,
wherein 10 of the 15 papers evaluated were separated by
≤1 point and the top 4 papers by ≤0.4 points, was "fierce."
The best score and winner of the "Excellence in Transla-
tional Medicine Award" was Xinmei Zhu and colleagues
from the University of Pittsburgh School of Medicine;
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Pittsburgh Cancer Center; Geneva University and Oncovir
for the paper entitled: "Toll-like receptor-3 ligand poly-
ICLC promotes the efficacy of peripheral vaccinations
with tumor antigen-derived peptide epitopes in murine
CNS tumor models" [2].
Exemplifying the criteria for the "Excellence in Transla-
tional Medicine Award," Zhu et al. [2] proceeded from a
potentially clinically relevant hypothesis through utiliza-
tion of a sound research design with rigorous methodol-
ogy to demonstrate with clarity that poly-ICLC
(polyinosinic-polycytidylic acid stabilized with poly-
lysine and carboxymethylcellulose) assisted antigen-spe-
cific peripheral vaccinations may represent an efficacious
and safe therapeutic approach for central nervous system
tumors.
The papers by the other three finalists: Kluger et al. [3];
Provenzano et al. [4] and Grasso et al. [5] on the subjects
of the x-linked inhibitor of apoptosis protein in metastatic
melanoma, characterization of the p53-binding domains
of the human polyomavirus BK tumor antigen, and ejacu-
latory disorders and the effects of α1-adrenoreceptor
antagonists therapy, all translational related topics fol-
lowed as listed, where but separated by a hair from the
winning paper by Zhu et al. [2].
With congratulations to Xinmei Zhu and colleagues [2],
the 1st "Excellence in Translational Medicine Award" is
now history. We are hopeful this Award will serve to
encourage other investigators devoted to improving the
"bench to bedside" concept of translational medicine and
initiatives in this direction. And, with the competition
now open for the 2nd "Excellence in Translational Medi-
cine Award," we very much look forward to the opportu-
nity of selecting next year's winning paper.
*"Excellence in Translational Medicine Award Commit-
tee": Richard J. Ablin (Co-Chairman); Howard L.
Kaufman; Bruce Littman; Upender Manne; Pier Giorgio
Natali; Hideho Okada; Michael Perricone; Raj K. Puri;
Noriyuki Sato; Patrick F. Terry; Craig Webb and Yi-Xin
Zeng (Co-Chairman).
References
1. Brander C, Ferrone S, Marincola F: Rewarding patient-directed
research: Excellence in Translational Medicine Award.  J
Transl Med 2006, 4:19.
2. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al.: Toll
like receptor-3 ligand poly-ICLC promotes the efficacy of
peripheral vaccinations with tumor-antigen-derived peptide
epitopes in murine CNS tumor models.  J Transl Med 2007,
5:10.
3. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL,
et al.: The x-linked inhibitor of apoptosis protein (XIAP) is up-
regulated in metastatic melanoma, and XIAP cleavage by
Phenoxodiol is associated with Carboplatin sensitization.  J
Transl Med 2007, 5:6.
4. Provenzano M, Bracci L, Wyler S, Hudolin T, Sais G, Gosert R, et al.:
Characterization of highly frequent epitope-specific
CD45A+/-/CCR7+/- T lymphocyte responses against p53-bind-
ing domains of the human polyomavirus BK large tumor
antigen in HLA-A*0201+ BKV-seropositive donors.  J Transl
Med 2006, 4:47.
5. Grasso M, Fortuna F, Lania C, Blanco S: Ejaculatory disorders and
α1-adrenoceptor antagonists therapy: clinical and experi-
mental researches.  J Transl Med 2006, 4:31.